Top Markets
Coin of the day
GSK plc GSK plc

GSK plc

GSK
Rangering i aksjer #199
GSK plc, together with its subsidiaries, engages in the creation, discovery,... GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Aksjekurs
$51.99
Markedsverdi
$104.42B
Endring (1 dag)
0.29%
Endring (1 år)
32.49%
Land
GB
Handel GSK plc (GSK)

Kategori

P/E-forhold for GSK plc (GSK)
P/E-forhold per March 2026 TTM: 14.28
Ifølge GSK plc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 14.28. Ved slutten av 2024 hadde selskapet en P/E på 21.32.
P/E-forholdshistorikk for GSK plc fra 2000 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) 14.28 10.44%
2025 12.93 -39.35%
2024 21.32 78.79%
2023 11.92 208.12%
2022 3.87 -67.35%
2021 11.85 26.27%
2020 9.39 -38.69%
2019 15.31 -6.32%
2018 16.34 -52.05%
2017 34.08 -49.33%
2016 67.26 956.89%
2015 6.36 -67.19%
2014 19.40 67.62%
2013 11.57 -1.74%
2012 11.78 3.64%
2011 11.36 -63.56%
2010 31.18 219.11%
2009 9.77 -16.60%
2008 11.72 7.01%
2007 10.95 -5.13%
2006 11.54 -19.65%
2005 14.36 -0.89%
2004 14.49 8.99%
2003 13.30 -8.11%
2002 14.47 -46.94%
2001 27.27 22.42%
2000 22.28 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
42.86 200.15%
US
28.47 99.34%
GB
21.88 53.24%
US
92.55 548.10%
US
20.85 46.00%
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.